S-1 Monotherapy as second-line treatment for advanced pancreatic cancer after gemcitabine failure

Japanese Journal of Clinical Oncology

Volumn 40, Issue 6, 2010, Pages 567-572

  Todaka, Akiko ^a   Fukutomi, Akira ^a   Boku, Narikazu ^a   Onozawa, Yusuke ^a   Hironaka, Shuichi ^a   Yasui, Hirofumi ^a   Yamazaki, Kentaro ^a   Taku, Keisei ^a   Machida, Nozomu ^a   Sakamoto, Takeshi ^a   Tomita, Hideharu ^a  

^a SHIZUOKA CANCER CENTER   (Japan)

Author keywords

Gemcitabine failure; Pancreatic cancer; S 1 monotherapy; Second line

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; GEMCITABINE; ANTINEOPLASTIC ANTIMETABOLITE; DEOXYCYTIDINE; DRUG DERIVATIVE; OXONIC ACID; S 1 (COMBINATION); TEGAFUR;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; ARTICLE; CANCER FATIGUE; CANCER SURVIVAL; CHOLANGITIS; CLOSTRIDIUM DIFFICILE INFECTION; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NAUSEA; PANCREAS CANCER; SIDE EFFECT; STOMATITIS; TREATMENT RESPONSE; DISEASE FREE SURVIVAL; DRUG COMBINATION; DRUG RESISTANCE; MIDDLE AGED; MORTALITY; PANCREAS TUMOR; SURVIVAL RATE;

ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; DRUG COMBINATIONS; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MIDDLE AGED; OXONIC ACID; PANCREATIC NEOPLASMS; SURVIVAL RATE; TEGAFUR;

EID: 77953419670     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyq005     Document Type: Article

References (43)

1. Burris HA, III, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997;15:2403-13.
2. Heinemann V, Boeck S, Hinke A, Labianca R, Louvet C. Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer. BMC Cancer 2008;8:82.
3. Louvet C, Labianca R, Hammel P, Lledo G, Zampino MG, André T, et al. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol 2005;23:3509-16.
4. Poplin E, Levy DE, Berlin J, Rothenberg M, Cella D, Mitchell E, et al. Phase III trial of gemcitabine (30-minute infusion) versus gemcitabine (fixed-dose rate-infusion [FDR]) versus gemcitabine + oxaliplatin (GEMOX) in patients with advanced pancreatic cancer (E6201). J Clin Oncol 2006;24: abstract LBA4004.
5. Heinemann V, Quietzsch D, Gieseler F, Gonnermann M, Schoenekaes H, Rost A, et al. Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J Clin Oncol 2006;24:3946-52.
6. Colucci G, Giuliani F, Gebbia V, Biglietto M, Rabitti P, Uomo G, et al. Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a prospective, randomized phase III study of the Gruppo Oncologico dell'Italia Meridionale. Cancer 2002;94:902-10.
7. Viret F, Ychou M, Lepille D, Mineur L, Navarro F, Topart D, et al. Gemcitabine in combination with cisplatin (GP) versus gemcitabine (G) alone in the treatment of locally advanced or metastatic pancreatic cancer: final results of a multicenter randomized phase II study. J Clin Oncol 2004;22(14S): abstract 4118.
8. Berlin J, Catalano P, Thomas J, Kugler JW, Haller DG, Benson AB. A phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group trial E2297. J Clin Oncol 2002;20:3270-5.
9. Riess H, Helm A, Niedergethmann M, Schmit-Wolf I, Moik M, Hammer C, et al. A randomised,prospective, multicenter, phase III trial of gemcitabine, 5-fluorouracil (5-FU), folinic acid vs. gemcitabine alone in patients with advanced pancreatic cancer. JClinOncol 2005;23(16S): abstract 4009.
10. Di Costanzo F, Carlini P, Doni L, Massidda B, Mattoioli R, Iop A, et al. Gemcitabine with or without continuous infusion 5-FU in advanced pancreatic cancer: a randomised phase II trial of the Italian oncology group for clinical research (GOIRC). Br J Cancer 2005;93:185-9.
11. Scheithauer W, Schull B, Ulrich-Pur H, Schmid K, Raderer M, Haider K, et al. Biweekly high-dose gemcitabine alone or in combination with capecitabine in patients with metastatic pancreatic adenocarcinoma: a randomized phase II trial. Ann Oncol 2003;14:97-104.
12. Herrmann R, Bodoky G, Ruhstaller T, Glimelius B, Saletti P, Bajetta E, et al. Gemcitabine (G) plus capecitabine (C) versus G alone in locally advanced or metastatic pancreatic cancer. A randomized phase III study of the Swiss Group for Clinical Cancer Research (SAKK) and the Central European Cooperative Group (CECOG). J Clin Oncol 2005;23: abstract 4010.
13. Cunningham D, Chau I, Stocken D, Davies C, Dunn J, Valle J, et al. Phase III randomised comparison of gemcitabine (GEM) versus gemcitabine plus capecitabine (GEM-CAP) in patients with advanced pancreatic cancer. Eur J Cancer 2005;3: abstract PS11 (suppl).
14. Oettle H, Richards D, Ramanathan RK, van Laethem JL, Peeters M, Fuchs M, et al. A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer. Ann Oncol 2005;16:1639-45.
15. Rocha Lima CM, Green MR, Rotche R, Miller WH, Jeffrey GM, Cisar LA, et al. Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J Clin Oncol 2004;22:3776-883.
16. Stathopoulos GP, Syrigos K, Aravantinos G, Polyzos A, Papakotoulas P, Fountzilas G, et al. A multicentre phase III trial comparing irinotecan-gemcitabine (IG) with gemcitabine (G) monotherapy as first-line treatment in patients with locally advanced or metastatic pancreatic cancer. Br J Cancer 2006;95:587-92.
17. O'Reilly EM, Abou-Alfa GK, Letourneau R, Harker WG, Modiano M, Hurwitz H, et al. A randomized phase III trial of DX-8951f (exatecan mesylate; DX) and gemcitabine (GEM) vs. gemcitabine alone in advanced pancreatic cancer (APC). J Clin Oncol 2004;22: abstract 4006.
18. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007;25:1960-6.
19. Morizane C, Okusaka T, Furuse J, Ishii H, Ueno H, Ikeda M, et al. A phase II study of S-1 in gemcitabine-refractory metastatic pancreatic cancer. Cancer Chemother Pharmacol 2009;63:313-9.
20. Ulrich-Pur H, Raderer M, Kornek GV, Schüll B, Schmid K, Haider K, et al. Irinotecan plus raltitrexed vs raltitrexed alone in patients with gemcitabine-pretreated advanced pancreatic adenocarcinoma. Br J Cancer 2003;88:1180-4.
21. Cantore M, Rabbi C, Fiorentini G, Oliani C, Zamagni D, Iacono C, et al. Combined irinotecan and oxaliplatin in patients with advanced pre-treated pancreatic cancer. Oncology 2004;67:93-7.
22. Milella M, Gelibter A, Di Cosimo S, Bria E, Ruggerl EM, Carllnl P, et al. Pilot study of celecoxib and infusional 5-fluorouracil as second-line treatment for advanced pancreatic carcinoma. Cancer 2004;101:133-8.
23. Tsavaris N, Kosmas C, Skopelitis H, Gouveris P, Kopteridis P, Loukeris D, et al. Second-line treatment with oxaliplatin, leucovorin and 5-fluorouracil in gemcitabine-pretreated advanced pancreatic cancer: a phase II study. Invest New Drugs 2005;23:369-75.
24. Ignatiadis M, Polyzos A, Stathopoulos GP, Tselepatiotis E, Christophylakis C, Kalbakis K, et al. A multicenter phase II study of docetaxel in combination with gefitinib in gemcitabine-pretreated patients with advanced/metastatic pancreatic cancer. Oncology 2006;71:159-63.
25. Demols A, Peeters M, Polus M, Marechal R, Monsaert E, Hendlisz A, et al. Gemcitabine and oxaliplatin (GEMOX) in gemcitabine refractory advanced pancreatic adenocarcinoma: a phase II study. Br J Cancer 2006;94:481-5.
26. Reni M, Pasetto L, Aprile G, Cordio S, Bonetto E, Dell'Oro S, et al. Raltitrexed-eloxatin salvage chemotherapy in gemcitabine-resistant metastatic pancreatic cancer. Br J Cancer 2006;94:785-91.
27. Kulke MH, Blaszkowsky LS, Ryan DP, Clark JW, Meyerhardt JA, Zhu AX, et al. Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancer. J Clin Oncol 2007;25:4787-92.
28. Boeck S, Weigang-Köhler K, Fuchs M, Kettner E, Quietzsch D, Trojan J, et al. Second-line chemotherapy with pemetrexed after gemcitabine failure in patients with advanced pancreatic cancer: a multicenter phase II trial. Ann Oncol 2007;18:745-51.
29. Yi SY, Park YS, Kim HS, Jun HJ, Kim KH, Chang MH, et al. Irinotecan monotherapy as second-line treatment in advanced pancreatic cancer. Cancer Chemother Pharmacol. 2009;63:1141-5.
30. Reni M, Cereda S, Mazza E, Passoni P, Nicoletti R, Balzano G, et al. PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) regimen as second-line therapy in patients with progressive or recurrent pancreatic cancer after gemcitabine-containing chemotherapy. Am J Clin Oncol 2008;31:145-50.
31. Xiong HQ, Varadhachary GR, Blais JC, Hess KR, Abbruzzese JL, Wolff RA. Phase 2 trial of oxaliplatin plus capecitabine (XELOX) as second-line therapy for patients with advanced pancreatic cancer. Cancer 2008;113:2046-52.
32. Boeck S, Wilkowski R, Bruns CJ, Issels RD, Schulz C, Moosmann N, et al. Oral Capecitabine in Gemcitabine-pretreated patients with advanced pancreatic cancer. Oncology 2007;73:221-7.
33. Reni M, Panucci MG, Passoni P, Bonetto E, Nicoletti R, Ronzoni M, et al. Salvage chemotherapy with mitomycin, docetaxel, and irinotecan (MDI regimen) in metastatic pancreatic adenocarcinoma: a phase I and II trial. Cancer Invest. 2004;22:688-96.
34. Kim YJ, Bang S, Park JY, Park SW, Chung JB, Sng SY.PhaseII study of 5-fluorouracil and paclitaxel in patients with gemcitabine-refractory pancreatic cancer. Cancer Chemother Pharmacol 2009; 63:529-33.
35. Cereda S, Reni M. Weekly Docetaxel as Salvage Therapy in Patients with Gemcitabine-Refractory Metastatic Pancreatic Cancer. J Chemother 2008;20:509-12.
36. Ko AH, Dito E, Schillinger B, Venook AP, Bergsland EK, Tempero MA. Excess toxicity associated with docetaxel and irinotecan in patients with metastatic, gemcitabine-refractory pancreatic cancer: results of a Phase II Study. Cancer Invest 2008;26:47-52.
37. Burris HA, III, Rivkin S, Reynolds R, Harris J, Wax A, Gerstein H, et al. Phase II trial of oral rubitecan in previously treated pancreatic cancer patients. The Oncologist 2005;10:183-90.
38. Novarino A, Satolli MA, Chiappino I, Giacobino A, Bellone G, Rahimi F, et al. Oxaliplatin, 5-fluorouracil, and leucovorin as second-line treatment for advanced pancreatic cancer. Am J Clin Oncol 2009;32:44-8.
39. Shirasaka T, Shimamato Y, Ohshimo H, Yamaguchi M, Kato T, Yonekura K, et al. Development of a novel form of an oral 5-fluorouracil derivative(S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs 1996;7:548-57.
40. Okusaka T, Funakoshi A, furuse J, Boku N, Yamao K, Ohkawa S, et al. A late phase II study of S-1 for metastatic pancreatic cancer. Cancer Chemother Pharmacol 2008;61:615-21.
41. NCCN Clinical Practice Guidelines in Oncology. Pancreatic Adenocarcinoma, v. 1. 2008. http://www.nccn.org/professionals/physician_gls/PDF/pancreatic.pdf.
42. Oettle H, Pelzer U, Stieler J, et al. Oxaliplatin/fornic acid/5-fluorouracil [24 h] (OFF) plus best supportive care alone (BSC) in second-line therapy of gemcitabine-refractory advanced pancreatic cancer (CONKO 003). J Clin Oncol 2005;23: abstract 4031.
43. Pelzer U, Kubica K, Stieler J, Schwaner I, Heil G, Görner M, et al. A randomized trial in patients with gemcitabine refractory pancreatic cancer. Final results of the CONKO 003 study. JClinOncol2008;26: abstract 4508.